Boothbay Fund Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Boothbay Fund Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-85,649	Closed	-$492K	–	1508
2024 Q4	$492K	Sell	85,649 -63,776	-43%	-$611K	0.01%	872
2024 Q3	$1.55M	Sell	149,425 -333,851	-69%	-$4.37M	0.04%	610
2024 Q2	$6.27M	Buy	483,276 +94,676	+24%	+$1.28M	0.15%	161
2024 Q1	$6.78M	Buy	+388,600	New	+$5.14M	0.13%	150
2020 Q3	–	Sell	-20,000	Closed	-$1M	–	1090
2020 Q2	$1M	Sell	20,000 -4,000	-17%	-$207K	0.07%	383
2020 Q1	$1.23M	Sell	24,000 -4,000	-14%	-$213K	0.1%	251
2019 Q4	$1.73M	Hold	28,000	–	–	0.15%	189
2019 Q3	$1.68M	Buy	28,000 +12,000	+75%	+$891K	0.15%	179
2019 Q2	$1.35M	Buy	+16,000	New	+$1.44M	0.12%	204

Other funds holding ENTA

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Boothbay Fund Management's ENTA Position: Q1 2025 in Review

Boothbay Fund Management sold out of Enanta Pharmaceuticals (ENTA) in Q1 2025, closing a stake of 85,649 shares — an estimated $492K sold.

Boothbay Fund Management first reported a position in ENTA in Q2 2019 and held it in 9 quarters. The position peaked at $6.78M in Q1 2024. 109 funds tracked by Wall St. Rank hold ENTA as of Q1 2025.

Boothbay Fund Management reported no remaining Enanta Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Boothbay Fund Management sold 85,649 Enanta Pharmaceuticals shares in Q1 2025, an estimated $492K.
Boothbay Fund Management first reported a position in Enanta Pharmaceuticals in Q2 2019 and held it in 9 quarters.
Boothbay Fund Management's Enanta Pharmaceuticals position peaked at $6.78M in Q1 2024.
109 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2025.

Based on Boothbay Fund Management's 13F filing for Q1 2025, filed 15 May 2025.